Assessment of TP53 Lesions for P53 System Functionality and Drug Resistance in Multiple Myeloma Using an Isogenic Cell Line Model

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-54407-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

Cancer Research
Cancer ResearchOncology
2008English

Activity of EGFR, mTOR and PI3K Inhibitors in an Isogenic Breast Cell Line Model

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2019English

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2006English

Targeting the Fanconi Anemia/Brca Pathway Circumvents Drug Resistance in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2009English

Molecular Characterisation of Isogenic Taxane Resistant Cell Lines Identify Novel Drivers of Drug Resistance

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Clinical Implications of Cytogenetic Heterogeneity in Multiple Myeloma Patients With TP53 Deletion

Modern Pathology
Forensic MedicinePathology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy